MA45469A - Acides nucléiques de bêta-caténine et leurs utilisations - Google Patents
Acides nucléiques de bêta-caténine et leurs utilisationsInfo
- Publication number
- MA45469A MA45469A MA045469A MA45469A MA45469A MA 45469 A MA45469 A MA 45469A MA 045469 A MA045469 A MA 045469A MA 45469 A MA45469 A MA 45469A MA 45469 A MA45469 A MA 45469A
- Authority
- MA
- Morocco
- Prior art keywords
- beta
- nucleic acids
- catenin nucleic
- catenin
- acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317123P | 2016-04-01 | 2016-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45469A true MA45469A (fr) | 2019-02-06 |
Family
ID=59965299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045469A MA45469A (fr) | 2016-04-01 | Acides nucléiques de bêta-caténine et leurs utilisations |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10844385B2 (fr) |
| EP (1) | EP3436582B1 (fr) |
| MA (1) | MA45469A (fr) |
| WO (1) | WO2017173297A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA45469A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques de bêta-caténine et leurs utilisations |
| WO2023122317A2 (fr) * | 2021-12-23 | 2023-06-29 | Aligos Therapeutics, Inc. | MOLÉCULES D'ACIDE NUCLÉIQUE INTERFÉRENT COURT (SINA) POUR CIBLER LA β-CATÉNINE ET LEURS UTILISATIONS |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1268404A (fr) | 1985-03-15 | 1990-05-01 | Antivirals Inc. | Reactif et methode pour le dosage des polynucleotides |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| DE552178T1 (de) | 1990-10-12 | 1994-02-03 | Max Planck Gesellschaft | Abgeänderte ribozyme. |
| DE4216134A1 (de) | 1991-06-20 | 1992-12-24 | Europ Lab Molekularbiolog | Synthetische katalytische oligonukleotidstrukturen |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
| US5716824A (en) | 1995-04-20 | 1998-02-10 | Ribozyme Pharmaceuticals, Inc. | 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes) |
| US5889136A (en) | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
| ATE373672T1 (de) | 1996-01-16 | 2007-10-15 | Sirna Therapeutics Inc | Synthese von methoxynukleoside und enzymatische nukleisäure moleküle |
| US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6111086A (en) | 1998-02-27 | 2000-08-29 | Scaringe; Stephen A. | Orthoester protecting groups |
| AU3751299A (en) | 1998-04-20 | 1999-11-08 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| CA2328356A1 (fr) | 1999-12-22 | 2001-06-22 | Itty Atcravi | Vehicules recreatifs |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| US8273866B2 (en) | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
| EP2361981B2 (fr) | 2000-03-30 | 2019-01-23 | The Whitehead Institute for Biomedical Research | Médiateurs spécifiques de la séquence d'ARN d'interférence d'ARN |
| ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
| RU2322500C2 (ru) | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
| US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| DE10133858A1 (de) | 2001-07-12 | 2003-02-06 | Aventis Pharma Gmbh | Synthetische doppelsträngige Oligonucleotide zur gezielten Hemmung der Genexpression |
| US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| US20040023220A1 (en) | 2002-07-23 | 2004-02-05 | Lawrence Greenfield | Integrated method for PCR cleanup and oligonucleotide removal |
| US7956176B2 (en) | 2002-09-05 | 2011-06-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| ES2357116T5 (es) | 2003-06-02 | 2021-09-03 | Univ Massachusetts | Métodos y composiciones para mejorar la eficacia y especificad de FNAi |
| US7750144B2 (en) | 2003-06-02 | 2010-07-06 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
| EP3502252B1 (fr) | 2003-06-02 | 2023-04-05 | University of Massachusetts | Procédés et compositions permettant de contrôler l'efficacité du silençage d'un arn |
| DK2336317T3 (da) | 2003-06-13 | 2019-12-16 | Alnylam Europe Ag | Dobbeltstrenget ribonukleinsyre med forøget effektivitet i en organisme |
| EP1742958B1 (fr) | 2004-03-15 | 2017-05-17 | City of Hope | Procedes et compositions pour l'inhibition specifique de l'expression genetique par l'arn double brin |
| AU2005247509C1 (en) | 2004-05-27 | 2012-09-20 | Alnylam Pharmaceuticals, Inc. | Nuclease resistant double-stranded ribonucleic acid |
| WO2008109369A2 (fr) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Composés d'acide nucléique permettant d'inhiber l'expression de gène tnf et utilisations de ceux-ci |
| DK2195428T3 (en) | 2007-09-19 | 2014-03-03 | Applied Biosystems Llc | SIRNA SEQUENCE-INDEPENDENT MODIFICATION FORMS TO REDUCE TARGET-FAILING PHENOTYPIC EFFECTS OF RNAI, AND STABILIZED FORMS THEREOF |
| WO2009099942A2 (fr) | 2008-01-31 | 2009-08-13 | Alnylam Pharmaceuticals, Inc. | Oligonucléotides modifiés chimiquement et leurs utilisations |
| AU2009213147A1 (en) | 2008-02-11 | 2009-08-20 | Rxi Pharmaceuticals Corp. | Modified RNAi polynucleotides and uses thereof |
| WO2010028054A1 (fr) | 2008-09-02 | 2010-03-11 | Alnylam Europe Ag. | Compositions et procédés d'inhibition de l'expression d'un gène egfr mutant |
| EP2340309A2 (fr) | 2008-09-22 | 2011-07-06 | Rxi Pharmaceuticals Corporation | Nanotransporteurs neutres |
| WO2010093788A2 (fr) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Molécules d'arn interférence substrats de dicer multiplexes ayant des séquences de jonction |
| CN102459298A (zh) | 2009-05-05 | 2012-05-16 | 阿尔特姆恩科技责任有限公司 | 化学可编程免疫 |
| AU2010324658A1 (en) * | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
| DK3037538T3 (da) * | 2010-07-06 | 2019-06-24 | Dicerna Pharmaceuticals Inc | Fremgangsmåder og sammensætninger til specifik inhibering af beta-catenin ved hjælp af dobbeltstrenget rna |
| CN107090456B (zh) * | 2010-08-02 | 2022-01-18 | 瑟纳治疗公司 | 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制 |
| BR112014001244A2 (pt) | 2011-07-19 | 2017-02-21 | Wave Life Sciences Pte Ltd | métodos para a síntese de ácidos nucléicos funcionalizados |
| KR102534909B1 (ko) | 2011-11-18 | 2023-05-30 | 알닐람 파마슈티칼스 인코포레이티드 | 변형된 ＲＮＡｉ 제제 |
| EP2844261B1 (fr) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | Compositions de petit acide nucléique interférent (sina) |
| AR090905A1 (es) * | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
| US9982257B2 (en) | 2012-07-13 | 2018-05-29 | Wave Life Sciences Ltd. | Chiral control |
| EA201591590A1 (ru) * | 2013-03-27 | 2016-05-31 | Исарна Терапьютикс Гмбх | Модифицированные олигонуклеотиды трф-бета |
| US9861574B2 (en) | 2013-04-09 | 2018-01-09 | Duke University | 2-fluoro-modified RNAs as immunostimulators |
| EP3610884B1 (fr) * | 2013-11-06 | 2021-08-18 | Merck Sharp & Dohme Corp. | Conjugués contenant des peptides pour double distribution moléculaire d'oligonucléotides |
| CN113278617A (zh) | 2014-01-16 | 2021-08-20 | 波涛生命科学有限公司 | 手性设计 |
| CA2953347A1 (fr) | 2014-06-23 | 2015-12-30 | Monsanto Technology Llc | Compositions et methodes de regulation de l'expression genetique par interference par arn |
| SG11201701166UA (en) | 2014-08-20 | 2017-03-30 | Alnylam Pharmaceuticals Inc | Modified double-stranded rna agents |
| MA45469A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques de bêta-caténine et leurs utilisations |
-
0
- MA MA045469A patent/MA45469A/fr unknown
-
2017
- 2017-03-31 US US15/476,341 patent/US10844385B2/en active Active
- 2017-03-31 EP EP17776789.4A patent/EP3436582B1/fr active Active
- 2017-03-31 WO PCT/US2017/025424 patent/WO2017173297A1/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017173297A1 (fr) | 2017-10-05 |
| EP3436582A4 (fr) | 2020-02-12 |
| EP3436582A1 (fr) | 2019-02-06 |
| US20170314030A1 (en) | 2017-11-02 |
| US10844385B2 (en) | 2020-11-24 |
| EP3436582B1 (fr) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR24C1023I1 (fr) | Anticorps thérapeutiques et leurs utilisations | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
| MA46471A (fr) | Protéines actriib à variant et leurs utilisations | |
| MA46708A (fr) | Anticorps anti-pd1 et leurs utilisations | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| MA53400A (fr) | Hétéromultimères alk7: actriib et leurs utilisations | |
| MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
| DK3433368T3 (da) | Transreplikerende rna | |
| MA43552A (fr) | Protéines immunomodulatrices à variants de cd80 et leurs utilisations | |
| MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
| MA45235A (fr) | Anticorps anti-c5 et leurs utilisations | |
| MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
| MA53145A (fr) | Agents de liaison cd123 et leurs utilisations | |
| MA55044A (fr) | Hétéromultimères alk4:actriib et leurs utilisations | |
| MA43567A (fr) | Anticorps pacap et leurs utilisations | |
| MA43821A (fr) | Pyrimidines et variantes de celles-ci, et leurs utilisations | |
| MA45690A (fr) | Anticorps anti-tgfb, méthodes et utilisations | |
| MA46472A (fr) | Hétéromultimères alk4:actriib et leurs utilisations | |
| MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
| MA45233A (fr) | Anticorps anti-gitr et leurs utilisations | |
| MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations | |
| MA44262A (fr) | Bioconjugués et utilisations de ceux-ci | |
| MA44489A (fr) | Pyrimidines et variants de celles-ci, et leurs utilisations |